Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of one dose (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in decompensated cirrhosis after their first decompensation event, who are stabilized CTP 5-7 (A study to test whether BI 685509 helps people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver) who had bleeding in the esophagus or fluid accumulation in the belly)

Boehringer Ingelheim0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年5月9日

试验速览

暂无简介。

•Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
•Male or female who is equal to or older than 18 (or who is of legal age in countries where that is greater than 18) and is eadual to or younger than 75 years old at screening (Visit 1a)
•Diagnosis of cirrhosis due to non-cholestatic liver disease (including HCV, HBV, NASH, alcohol-related liver disease, autoimmune hepatitis, Wilsons disease, haemachromatosis, alpha-1 antitrypsin [A1At] deficiency)
•One previous clinically significant decompensation event with clinical resolution at least 4 weeks prior start of screening (visit 1a):
•a) First variceal haemorrhage
•b) First episode of clinically significant ascites (requiring intervention in lifestyle [fluid and salt restriction] or medical treatment)
•Willing and able to undergo HVPG measurements per protocol (based on Investigator judgement)

•History of cholestatic chronic liver disease (e.g. primary biliary cholangitis, primary sclerosing cholangitis)
•Trial participants without adequate treatment for HBV, HCV or NASH as per local guidance (e.g. antiviral therapy for chronic HBV or HCV infection or lifestyle modification in NASH)
•If received curative anti-viral therapy for HCV, SVR sustained for less than 1 years prior to screening
•If receiving anti-viral therapy for HBV, less than 6 months on a stable dose prior to screening, with planned dose change during the trial or HBV DNA detectable
•Weight change more than eaqual to 5 percent within 6 months prior screening in patients with NASH
•Must take, or wishes to continue the intake of, restricted concomitant therapy or any concomitant therapy considered likely (based on Investigator judgement) to interfere with the safe conduct of the trial
•SBP less than 100 mmHg or DBP less than 70 mmHg at screening (Visit 1a)
•Hepatic impairment defined as a Child-Turcotte-Pugh score eaqual to or greater than 8 at screening

Percentage change in HVPG from baseline (measured in mmHg) after 8 weeks of treatment.

Occurrence of a response(after 8 weeks of treatment)
Occurrence of one or more decompensation events(during the 8 week treatment period)
Occurrence of CTCAE grade 3 (or higher) hypotension or syncope(during the 8 week treatment period)

发起方